# Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma

> **NCT02847559** · PHASE2 · RECRUITING · sponsor: **Northwestern University** · enrollment: 27 (estimated)

## Conditions studied

- Anaplastic (Malignant) Meningioma
- Atypical Meningioma
- Grade II Meningioma
- Grade III Meningioma
- Recurrent Meningioma
- Supratentorial Meningioma

## Interventions

- **BIOLOGICAL:** Bevacizumab
- **PROCEDURE:** Electric Field Therapy
- **DEVICE:** NovoTTF-200A Device
- **PROCEDURE:** Quality-of-Life Assessment

## Key facts

- **NCT ID:** NCT02847559
- **Lead sponsor:** Northwestern University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2016-08-01
- **Primary completion:** 2026-09
- **Final completion:** 2026-12
- **Target enrollment:** 27 (ESTIMATED)
- **Last updated:** 2025-06-27

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02847559

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02847559, "Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT02847559. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*